Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer's And Dementia Treatment
Portfolio Pulse from Vandana Singh
Nexalin Technology Inc. (NASDAQ:NXL) has been awarded a U.S. patent for its noninvasive Deep Intracranial Frequency Stimulation (DIFS) medical device, designed to treat Alzheimer's and other dementia-related brain diseases. The device uses a proprietary frequency-based waveform for pain-free treatment. The global dementia treatment market is projected to grow significantly, and Nexalin's device could revolutionize care for various neurological diseases.
June 20, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nexalin Technology Inc. (NXL) has received a U.S. patent for its DIFS medical device, which treats Alzheimer's and dementia. The device's potential to revolutionize treatment in a growing market has driven NXL shares up 36.5% in premarket trading.
The award of a U.S. patent for a device targeting a significant and growing market like dementia treatment is a major milestone for Nexalin Technology. The market's positive reaction, with shares up 36.5% premarket, indicates strong investor confidence in the potential of this technology.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100